Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.
Katharina M DetjenRaik OttoYvonne GieseckeLukas GeislerPamela RiemerHenning JannCarsten GrötzingerChristine SersAndreas PascherTom LüddeUlf LeserBertram WiedenmannMichael SigalFrank TackeChristoph RoderburgLinda HammerichPublished in: Cancers (2021)
We propose Flt3L as a prognostic biomarker for high grade GEP-NEN, harnessing its potential as a marker of an inflammatory tumor microenvironment. Flt3L measurements in serum, which can be easily be incorporated into clinical routine, should be further evaluated to guide patient stratification and treatment decisions.